Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.

VanDevanter DR, Mayer-Hamblett N.

Curr Opin Pulm Med. 2017 Jul 13. doi: 10.1097/MCP.0000000000000418. [Epub ahead of print]

PMID:
28708817
2.

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention.

Konstan MW, Wagener JS, VanDevanter DR, Pasta DJ, Millar SJ, Morgan WJ; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2017 Aug;52(8):1013-1019. doi: 10.1002/ppul.23751. Epub 2017 Jul 3.

PMID:
28672067
3.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Apr 28. pii: S1569-1993(17)30101-7. doi: 10.1016/j.jcf.2017.04.005. [Epub ahead of print]

PMID:
28460885
4.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Apr 29. pii: S1569-1993(17)30099-1. doi: 10.1016/j.jcf.2017.04.003. [Epub ahead of print]

PMID:
28457954
5.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Jain R, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Apr 21. pii: S1569-1993(17)30100-5. doi: 10.1016/j.jcf.2017.04.004. [Epub ahead of print]

PMID:
28438499
6.

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis.

Morgan WJ, Wagener JS, Pasta DJ, Millar SJ, VanDevanter DR, Konstan MW; Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Ann Am Thorac Soc. 2017 Jun;14(6):937-942. doi: 10.1513/AnnalsATS.201608-615OC.

PMID:
28324670
7.

The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans?

Flume PA, VanDevanter DR.

Ann Intern Med. 2017 Apr 18;166(8):599-600. doi: 10.7326/M17-0564. Epub 2017 Mar 14. No abstract available.

PMID:
28289748
8.

Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation.

VanDevanter DR, Mayer-Hamblett N, Boyle M.

J Cyst Fibros. 2017 Jul;16(4):496-498. doi: 10.1016/j.jcf.2017.02.012. Epub 2017 Mar 9.

9.

The challenges of maintaining momentum in CF drug development and approval - Commentary.

Flume PA, VanDevanter DR.

J Cyst Fibros. 2017 Mar;16(2):170-171. doi: 10.1016/j.jcf.2017.01.014. Epub 2017 Feb 5. No abstract available.

PMID:
28179070
10.

BMI fails to identify poor nutritional status in stunted children with CF.

Konstan MW, Pasta DJ, Wagener JS, VanDevanter DR, Morgan WJ.

J Cyst Fibros. 2017 Jan;16(1):158-160. doi: 10.1016/j.jcf.2016.11.005.

PMID:
27916550
11.

Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies.

VanDevanter DR, Heltshe SL, LiPuma JJ.

Ann Am Thorac Soc. 2016 Nov;13(11):1890-1893.

PMID:
27518252
12.

Efficacy measures for clinical trials: A review series.

Flume PA, VanDevanter DR.

J Cyst Fibros. 2016 Jul;15(4):415. doi: 10.1016/j.jcf.2016.06.002. Epub 2016 Jun 15. No abstract available.

PMID:
27316664
13.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

VanDevanter DR, Flume PA, Morris N, Konstan MW.

J Cyst Fibros. 2016 Nov;15(6):783-790. doi: 10.1016/j.jcf.2016.04.005. Epub 2016 Apr 29.

14.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR.

J Cyst Fibros. 2016 Sep;15(5):634-40. doi: 10.1016/j.jcf.2016.01.005. Epub 2016 Feb 28.

PMID:
26935334
15.

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.

Mayer-Hamblett N, Boyle M, VanDevanter D.

Thorax. 2016 May;71(5):454-61. doi: 10.1136/thoraxjnl-2015-208123. Epub 2016 Feb 22. Review.

16.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS.

J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.

PMID:
26852040
17.

CFTR modulators and pregnancy: Our work has only just begun.

Goss CH, VanDevanter DR.

J Cyst Fibros. 2016 Jan;15(1):6-7. doi: 10.1016/j.jcf.2015.12.019. Epub 2016 Jan 7. No abstract available.

PMID:
26774758
18.

Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens.

Mahboubi MA, Carmody LA, Foster BK, Kalikin LM, VanDevanter DR, LiPuma JJ.

J Clin Microbiol. 2016 Mar;54(3):613-9. doi: 10.1128/JCM.02299-15. Epub 2015 Dec 23.

19.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.

VanDevanter DR, Morris NJ, Konstan MW.

J Cyst Fibros. 2016 May;15(3):372-9. doi: 10.1016/j.jcf.2015.10.006. Epub 2015 Oct 23.

20.

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment.

VanDevanter DR, Kahle JS, O'Sullivan AK, Sikirica S, Hodgkins PS.

J Cyst Fibros. 2016 Mar;15(2):147-57. doi: 10.1016/j.jcf.2015.09.008. Epub 2015 Oct 9. Review.

Supplemental Content

Loading ...
Support Center